← SynDRA
LESTAURTINIB
SynDRA canonical compound SYN0020499 — structure-anchored drug synonym record
| Clinical phase | Phase 2/Phase 3 |
| Primary target(s) | NTRK1 |
| Mechanism of action | Growth factor receptor inhibitor |
| Indication | acute myeloid leukemia (aml) |
| Disease area | Oncology |
All known targets
- FLT3
- NTRK1
- JAK2
- NTRK2
- NTRK3
- RET
Mechanisms of action (all sources)
- JAK inhibitor
- FLT3 INHIBITOR
- Growth factor receptor inhibitor
- Tyrosine-protein kinase receptor FLT3 inhibitor
- JAK2 INHIBITOR
- Tyrosine-protein kinase JAK2 inhibitor
- NTRK1 INHIBITOR
- Nerve growth factor receptor Trk-A inhibitor
- NTRK2 INHIBITOR
- Neurotrophic tyrosine kinase receptor type 2 inhibitor
- NTRK3 INHIBITOR
- NT-3 growth factor receptor inhibitor
Cross-references
Synonyms
- A-154475
- A-154475.0
- CEP-701
- KT-555
- KT-5555
- KT5555
- SP-924
- SP924
- SPM-924
- A 1544750
- SP 924
- Lestaurtinib (USAN/INN)
- CEP 701
- KT 5555
- CEP701
- C26H21N3O4
- CHEMBL603469
- DO989GC5D1
- A 154475.0
- (9S,10S,12R)-2,3,9,10,11,12-Hexahydro-10-hydroxy-10-(hydroxymethyl)-9-methyl-9,12-epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocin-1-one
- NCGC00168772-01
- (5S,6S,8R)-6-hydroxy-6-(hydroxymethyl)-5-methyl-7,8,14,15-tetrahydro-5H-16-oxa-4b,8a,14-triaza-5,8-methanodibenzo[b,h]cycloocta[jkl]cyclopenta[e]-as-indacen-13(6H)-one
- Lestaurtinib [USAN]
- Lestaurtinib [USAN:INN]
- UNII-DO989GC5D1
- 4otg
- CEP-701 hydrate
- Lestaurtinib; CEP701
- LESTAURTINIB [INN]
- LESTAURTINIB [MART.]
- LESTAURTINIB [WHO-DD]
- GTPL5672
- SCHEMBL1649693
- DTXSID5046778
- CHEBI:91471
- 9,12-Epoxy-1H-diindolo(1,2,3-fg:3',2',1'-kl)pyrrolo(3,4-i)(1,6)benzodiazocin-1-one, 2,3,9,10,11,12-hexahydro-10-hydroxy-10-(hydroxymethyl)-9-methyl-, (9S,10S,12R)-
- 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocin-1-one, 2,3,9,10,11,12-hexahydro-10-hydroxy-10-(hydroxymethyl)-9-methyl-, (9S,10S,12R)-
- BCP06977
Look up LESTAURTINIB in the interactive SynDRA portal →